test under section 587A. (F) Indications for use information under section 587(10). (G) Brief narrative description of the in vitro clinical test. (H) A brief summary of the analytical and clinical performance of the in vitro clinical test, and as applicable, the lot release criteria. (I) A brief description of conformance with any applicable mitigating measures, restrictions, and standards. (J) Representative labeling for the in vitro clinical test, as appropriate. (K) A statement that the information submitted is truthful and accurate. (3) Test listing number The Secretary may assign a test listing number to each in vitro clinical test that is the subject of a listing under this section. The process for assigning test listing numbers may be established through guidance, and may include the recognition of standards, formats, or conventions developed by a third-party organization. (4) Abbreviated listing A person who is not a developer but is otherwise required to register pursuant to subsection (a) shall submit an abbreviated listing to the Secretary containing the information described in subparagraphs (A) through (C) of paragraph (2), and the name of the developer. The information shall be submitted in accordance with the applicable schedule described under subsection (c). Such abbreviated listing shall be prepared in such form and manner as the Secretary may specify in guidance. Listing information shall be submitted to the comprehensive test information system in accordance with section 587T, as appropriate. (5) Grandfathered tests A developer of an in vitro clinical test developer offering a test that is grandfathered under section 587A(c) shall submit listing information required under subparagraphs (A) through (I) of paragraph (2). (6) Low-risk tests A developer of a low risk in vitro clinical test shall notify and submit listing information to the Secretary within one year of offering such test for clinical use. (7) Exempt tests A developer of an in vitro clinical test who introduces or proposes to